Avrobio Inc (NASDAQ:AVRO)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $17.67, but opened at $19.16. Avrobio shares last traded at $22.90, with a volume of 5,567,606 shares trading hands.

AVRO has been the topic of several research analyst reports. Janney Montgomery Scott initiated coverage on Amicus Therapeutics in a research report on Friday, April 5th. They set a “buy” rating and a $13.91 target price on the stock. Cowen restated a “buy” rating on shares of Avrobio in a research report on Monday. Mizuho initiated coverage on Avrobio in a research report on Wednesday, June 26th. They set a “buy” rating and a $28.00 target price on the stock. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Tuesday. Finally, HC Wainwright set a $25.00 target price on Onconova Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Avrobio has an average rating of “Buy” and an average price target of $27.90.

The business has a 50 day moving average of $14.99. The stock has a market capitalization of $396.49 million and a price-to-earnings ratio of -6.33.

Avrobio (NASDAQ:AVRO) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.01). On average, sell-side analysts expect that Avrobio Inc will post -2.93 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of AVRO. JPMorgan Chase & Co. raised its stake in Avrobio by 90.8% during the 1st quarter. JPMorgan Chase & Co. now owns 1,224,455 shares of the company’s stock worth $26,999,000 after buying an additional 582,639 shares during the period. BlackRock Inc. raised its stake in Avrobio by 73.4% during the 4th quarter. BlackRock Inc. now owns 651,959 shares of the company’s stock worth $10,854,000 after buying an additional 276,018 shares during the period. Emerald Advisers LLC raised its stake in Avrobio by 61.4% during the 1st quarter. Emerald Advisers LLC now owns 614,408 shares of the company’s stock worth $13,548,000 after buying an additional 233,772 shares during the period. Emerald Mutual Fund Advisers Trust raised its stake in Avrobio by 40.2% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 522,590 shares of the company’s stock worth $11,523,000 after buying an additional 149,725 shares during the period. Finally, Victory Capital Management Inc. raised its stake in Avrobio by 4,614.3% during the 1st quarter. Victory Capital Management Inc. now owns 136,761 shares of the company’s stock worth $3,016,000 after buying an additional 133,860 shares during the period. 71.13% of the stock is currently owned by institutional investors and hedge funds.

Avrobio Company Profile (NASDAQ:AVRO)

AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.

Recommended Story: What is Put Option Volume?

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.